阿帕替尼治疗胃癌及其他肿瘤的研究现状

被引：60

作者：

赵鹏飞

曹邦伟

机构：

[1] 首都医科大学附属北京友谊医院肿瘤科

来源：

临床与病理杂志 | 2016年 / 36卷 / 06期

关键词：

胃癌; 阿帕替尼; 临床试验; 血管生成;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

转移性胃癌是一类生存期很短的致死性恶性肿瘤,目前有许多针对晚期胃癌靶向治疗的研究,但结果并不理想,仅仅有少数靶向药物可以改善胃癌预后,如曲妥珠单抗和雷莫芦单抗。血管内皮生长因子(vascular endothelial growth factors,VEGF)与肿瘤发生发展密切相关,晚期胃癌患者中VEGF水平呈高表达,因此靶向VEGF被认为是胃癌治疗的新方向。在与血管生成相关的靶向药物中,阿帕替尼是一种靶向血管内皮生长因子受体2(vascular endothelial growth factors receptor,VEGFR2)的口服小分子受体酪氨酸激酶抑制剂,其口服生物利用度好并对胃癌有效。最新研究结果显示阿帕替尼作为三线方案可以改善胃癌患者生存结局,因此阿帕替尼很可能成为晚期胃癌治疗的关键药物。本文对阿帕替尼抗肿瘤机制、药代动力学、有效性及安全性、相关临床试验及最新研究进展简以综述。

引用

页码：815 / 823

页数：9

共 13 条

[1]

Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib [J].

Peng, Sui ;

Zhang, Yanyan ;

Peng, Hong ;

Ke, Zunfu ;

Xu, Lixia ;

Su, Tianhong ;

Tsung, Allan ;

Tohme, Samer ;

Huang, Hai ;

Zhang, Qiuyang ;

Lencioni, Riccardo ;

Zeng, Zhirong ;

Peng, Baogang ;

Chen, Minhu ;

Kuang, Ming .

CANCER LETTERS, 2016, 373 (02) :193-202

[2]

Global Cancer Statistics, 2012 [J].

Torre, Lindsey A. ;

Bray, Freddie ;

Siegel, Rebecca L. ;

Ferlay, Jacques ;

Lortet-Tieulent, Joannie ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (02) :87-108

[3]

Multicenter phase II study of apatinib; a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer.[J].Xichun Hu;Jian Zhang;Binghe Xu;Zefei Jiang;Joseph Ragaz;Zhongsheng Tong;Qingyuan Zhang;Xiaojia Wang;Jifeng Feng;Danmei Pang;Minhao Fan;Jin Li;Biyun Wang;Zhonghua Wang;Qunling Zhang;Si Sun;Chunmei Liao.Int. J. Cancer.2014, 8

[4]

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

[5]

Unmet needs and challenges in gastric cancer: The way forward [J].

Lordick, Florian ;

Allum, William ;

Carneiro, Fatima ;

Mitry, Emmanuel ;

Tabernero, Josep ;

Tan, Patrick ;

Van Cutsem, Eric ;

van de Velde, Cornelis ;

Cervantes, Andres .

CANCER TREATMENT REVIEWS, 2014, 40 (06) :692-700

[6]

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Yong, Cho Jae ;

Dumitru, Filip ;

Passalacqua, Rodolfo ;

Goswami, Chanchal ;

Safran, Howard ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David R. ;

Melichar, Bohuslav ;

Tehfe, Mustapha ;

Topuzov, Eldar ;

Zalcberg, John Raymond ;

Chau, Ian ;

Campbell, William ;

Sivanandan, Choondal ;

Pikiel, Joanna ;

Koshiji, Minori ;

Hsu, Yanzhi ;

Liepa, Astra M. ;

Gao, Ling ;

Schwartz, Jonathan D. ;

Tabernero, Josep .

LANCET, 2014, 383 (9911) :31-39

[7]

Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy [J].

Fan, Minhao ;

Zhang, Jian ;

Wang, Zhonghua ;

Wang, Biyun ;

Zhang, Qunlin ;

Zheng, Chunlei ;

Li, Ting ;

Ni, Chen ;

Wu, Zhenhua ;

Shao, Zhimin ;

Hu, Xichun .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (01) :141-151

[8]

Pazopanib: a promising new agent in the treatment of soft tissue sarcomas [J].

Kasper, Bernd ;

Hohenberger, Peter .

FUTURE ONCOLOGY, 2011, 7 (12) :1373-1383

[9]

Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.[J].Xiu-zhen Tong;Fang Wang;Shu Liang;Xu Zhang;Jie-hua He;Xing-Gui Chen;Yong-ju Liang;Yan-jun Mi;Kenneth Kin Wah To;Li-wu Fu.Biochemical Pharmacology.2011, 5

[10]

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

← 1 2 →